2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Expert faculty review and share their insights and perspectives on key findings in MDS and MPNs presented at the 2020 ASH Annual Meeting.
Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Slidesets Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis
Slidesets Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results
Slidesets CONTINUATION-PV: 5-Yr Results of Ropeginterferon α-2b in Polycythemia Vera
Slidesets Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis
Slidesets MANIFEST: Novel BET Inhibitor, CPI-0610, Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Patients
Slidesets Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS
Slidesets DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML
Slidesets BMT CTN 1102: RIC Allogeneic HSCT vs Non-HSCT Therapy in Patients 50-75 Yrs With Higher-risk MDS

Review expert perspectives on the most clinically relevant data on myelodysplastic syndromes and myeloproliferative neoplasms presented at the 2020 ASH annual meeting.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: February 16, 2021 Expired: February 15, 2022

In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in MDS and MPNs with the most potential to impact clinical practice.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 23, 2021

In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, PhD, discuss new data and studies in MDS and MPNs presented at ASH 2020.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 5, 2021
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings